We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson unit Janssen and AbbVie got the red light from the UK’s National Institute for Health and Care Excellence, which did not recommend the drug giants’ chronic lymphocytic leukemia drug Imbruvica.